Physician profile
John R Monroe
NPI 1346312451
$12,126.11
in general payments reported to CMS, 2019-2025
54 companies · $1,620 in 2025
The $1,620 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $941 · 2021: $2,453 · 2022: $2,241 · 2023: $1,841 · 2024: $1,745 · 2025: $1,620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,181 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,180.62 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,666.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,331.92 | 2021-2025 | |
| Glaxosmithkline, LLC. | $985.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $962.54 | 2019-2025 | |
| Abbott Laboratories | $871.54 | 2019-2025 | Assurity, Freestyle Libre 3, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.21 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $522.70 | 2021-2025 | |
| Lilly USA, LLC | $446.67 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Sanofi-Aventis U.S. LLC | $410.33 | 2019-2024 | |
| Astellas Pharma US INC | $405.14 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $386.05 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $380.01 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $305.97 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $270.00 | 2021 | |
| Daiichi Sankyo INC. | $225.75 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.